Onabotulinumtoxina Re-Injection for Refractory Detrusor Overactivity Using 3-4 Injection Sites: Results of a Pilot Study

Published:December 17, 2019DOI:



      To determine if repeated treatment with Onabot/A in less injections points, provides similar clinical efficacy, duration, and adverse events compared with previous treatment.


      Prospective data of neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO) patients previously treated with Onabot/A according to standard technique. When patients requested for repeating procedure, they were treated with the same Onabot/A dose but with 3-4 injection sites. Onabot/A injection was performed under local or spinal anaesthesia. Pain was evaluated with VAS pain scale. Efficacy was evaluated by the Treatment Benefit Scale (TBS) and attainment of complete continence. Duration of effect was determined by patient reported return of symptoms, and requested for repeating procedure. Adverse events were also reported.


      We report the results of 21 patients. Nineteen patients (90%) were female, 10 patients (48%) neurogenic, 9 (43%) were under clean intermittent catheterization. Procedure was performed under local anaesthesia in 20 patients (95%). Doses of Onabot/A used were 100-300 units with 3-4 injections sites. According to TBS, 86% of patients improved. Seventeen patients (81%) were continent after the procedure. Five patients (24%) presented urinary tract infection as adverse event. The mean duration of effect was 34.9 weeks compared with 35.6 weeks of previous procedure with no significant differences.


      We consider that treatment of Onabot/A with 3-4 injections may have similar clinical efficacy and duration of effect, compared to standard technique, with limited adverse events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cruz F
        • Herschorn S
        • Aliotta P
        • et al.
        Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
        Eur Urol [Internet]. 2011; 60: 742-750
        • Chapple C
        • Sievert K-D
        • MacDiarmid S
        • et al.
        OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
        Eur Urol. 2013; 64: 249-256
        • Coelho A
        • Cruz F
        • Cruz CD
        • Avelino A
        Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action.
        Eur Urol. 2012; 61: 1178-1184
        • Liao CH
        • Chen SF
        • Kuo HC
        Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study.
        Neurourol Urodyn. 2016; 35: 717-723
        • Avallone MA
        • Sack BS
        • El-Arabi A
        • Guralnick ML
        • Corey O’connor R
        Less is more—a pilot study evaluating one to three intradetrusor sites for injection of onabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
        Neurourol Urodyn. 2017 Apr; 36: 1104-1107
        • Karsenty G
        • Carsenac A
        • Boy S
        • et al.
        Eur Urol Suppl. 2007; 6: 245
        • Denys P
        • Del Popolo G
        • Amarenco G
        • Karsenty G
        • Le Berre P
        Efficay and safety of two administration modes.
        Neurourol Urodyn. 2017; 36: 457-462
        • Hsieh PF
        • Chiu HC
        • Chen KC
        • Chang CH
        • Chou ECL
        Botulinum toxin a for the treatment of overactive bladder.
        Toxins (Basel). 2016; 8: 1-12
        • Sievert KD
        • Chapple C
        • Herschorn S
        • et al.
        OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
        Int J Clin Pract. 2014; 68: 1246-1256
        • Colman S
        • Chapple C
        • Nitti V
        • Haag-Molkenteller C
        • Hastedt C
        • Massow U
        Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
        Urology. 2008; 72: 803-807
        • Errando-Smet C
        • Ruiz MA
        • Villacampa-Aubá F
        • et al.
        Adaptación cultural al Español y validación psicométrica de la Escala de Beneficio del Tratamiento (Treatment Benefit Scale -TBS) en el tratamiento sintomático de la vejiga hiperactiva.
        Med Clin (Barc). 2013; 140: 6-13
        • Jimenez-Cidre MA
        • Lopez-Fando L
        • Esteban-Fuertes M
        • et al.
        The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women.
        Neurourol Urodyn. 2015; 34: 128-132
        • Rovner E
        • Kohan A
        • Chartier-Kastler E
        • et al.
        Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment.
        J Urol. 2016; 196: 801-808
        • Karsenty G
        • Boy S
        • Reitz A
        Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-a prospective randomized study to compare 30 vs 10 injections sites.
        Neururol Urodyn. 2005; 4-6: 547-548
        • Nitti VW
        • Ginsberg D
        • Sievert K-D
        • Sussman D
        Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study.
        J Urol. 2016; 196: 791-800
        • Mangera A
        • Apostolidis A
        • Andersson KE
        • et al.
        An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
        Eur Urol. 2014 May; 65: 981-990
        • Arlandis Guzman S
        • López-Fando Lavalle L
        • Gallego A
        • Fabuel Alcañiz JJ
        • Broset AE
        • Jiménez-Cidre MA
        Onabotulinumtoxina injections for idiopathic and neurogenic overactive bladder: discontinuation rates and reasons for treatment disruption in two Spanish hospitals.
        Neurourol Urodyn. 2015; 34: S111
        • Kennelly M
        • Dmochowski R
        • Ethans K
        • et al.
        Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.
        Urology. 2013; 81: 491-497